"REtinal Markers In Neuroinflammatory Diseases (REMIND)"

RecruitingOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

February 28, 2029

Conditions
Multiple SclerosisNeuroinflammatory Diseases
Interventions
DIAGNOSTIC_TEST

Optical coherence tomography (OCT)

"OCT is used to measure:~* peripapillary retinal nerve fiber layer (mean thickness in μm)~* ganglion cell-inner plexiform layer (volume in mm\^3 and mean thickness in μm)~* other retinal layers (inner nuclear layer, outer plexiform layer, outer nerve layer; volumes in mm\^3 and mean thickness in μm).~The scanner laser ophthalmoscopy-function of the OCT device is used to continuously record the exact location of each participant's fixation point in relation to their fovea and thereby allows the assessment of the fixation instability.~In a subgroup of participants, the angiography-module of the OCT device is used to image the retinal blood flow and thereby allows to measure the vascular area density of the superficial retinal capillary plexus and deep retinal capillary plexus."

DIAGNOSTIC_TEST

Static retinal vessel analyzer

"Static retinal vessel analyzer is used to determine:~* central retinal arteriolar diameter equivalents (in μm)~* central retinal venular diameter equivalents (in μm)~* arteriolar-to-venular diameter ratio"

DIAGNOSTIC_TEST

Dynamic retinal vessel analyzer

In a subgroup of participants, the dynamic retinal vessel analyzer is used to determine the arteriolar ficker light-induced dilatation, venular ficker light-induced dilatation, and Arteriolar constriction, measured in % dilatation in comparison to baseline.

DIAGNOSTIC_TEST

Laser speckle flowgraphy system

In a subgroup of participants, the laser speckle flowgraphy system is used to measure the relative ocular blood flow as expressed in arbitary units of Mean Blur Rate.

OTHER

Questionnaire

All study participants will be asked to fill in a questionnaire with various questions regarding existing eye diseases, other diseases (including vascular diseases/risk factors), and daily physical activity that could influence the results of the retinal examinations. Physical activity will be assessed using an adapted form of the standardized Global Physical Activity Questionnaire.

Trial Locations (1)

4031

RECRUITING

University Hospital Basel, Department of Neurology, Basel

All Listed Sponsors
collaborator

University of Basel

OTHER

lead

University Hospital, Basel, Switzerland

OTHER